Firdapse (amifampridine) for Lambert-Eaton myasthenic syndrome (LEMS)
Defines coverage, prior authorization documentation requirements, initial and continuation approval criteria, exclusions, and quantity limits for Firdapse (amifampridine) for treatment of Lambert-Eaton myasthenic syndrome in adults and pediatric patients ≥6 years.
Reviewed June 2025 (policy reviewed).
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.